Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium By: TheNewswire.com - RSS (Media) September 28, 2023 at 14:02 PM EDT Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals Ltd (TSX-V:VM) (OTC:VYYRF). Appiah gives an overview of the note and the company itself, explaining that contrast agents containing barium sulphate or iodine are consumed prior to x-rays or CT scans, aiding doctors in visualizing the interior of the body. Voyageur aims to leverage its own facilities and resources to establish an integrated value chain for these agents in North America. The company has already launched its first product in Canada, with plans to expand to the US post-FDA approvals. By 2025, Voyageur intends to source barium from its fully-owned Frances Creek Mine, potentially reducing raw ingredient costs significantly. Appiah explains that Voyageur is currently seeking funding to help support its development. Contact DetailsProactive Investors+1 604-688-8158na-editorial@proactiveinvestors.com Related Stocks: Voyageur Pharmaceuticals Ltd Voyageur Pharmaceuticals Ltd Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Voyageur Pharmaceuticals "sees a gap in the market" for domestically-produced barium By: TheNewswire.com - RSS (Media) September 28, 2023 at 14:02 PM EDT Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals Ltd (TSX-V:VM) (OTC:VYYRF). Appiah gives an overview of the note and the company itself, explaining that contrast agents containing barium sulphate or iodine are consumed prior to x-rays or CT scans, aiding doctors in visualizing the interior of the body. Voyageur aims to leverage its own facilities and resources to establish an integrated value chain for these agents in North America. The company has already launched its first product in Canada, with plans to expand to the US post-FDA approvals. By 2025, Voyageur intends to source barium from its fully-owned Frances Creek Mine, potentially reducing raw ingredient costs significantly. Appiah explains that Voyageur is currently seeking funding to help support its development. Contact DetailsProactive Investors+1 604-688-8158na-editorial@proactiveinvestors.com Related Stocks: Voyageur Pharmaceuticals Ltd Voyageur Pharmaceuticals Ltd